Prévention et traitement de l’ostéoporose cortisonique

Khosla, 1994, Epidemiology and clinical features of osteoporosis in young individuals, Bone, 15, 551, 10.1016/8756-3282(94)90280-1 Manolagas, 1999, New developments in the pathogenesis and treatment of steroid-induced osteoporosis, J Bone Miner Res, 1061, 10.1359/jbmr.1999.14.7.1061 Weistein, 1998, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids, J Clin Invest, 102, 274, 10.1172/JCI2799 Plotkin, 1999, Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, J Clin Invest, 104, 1363, 10.1172/JCI6800 Weinstein, 2002, Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids, J Clin Invest, 109, 1041, 10.1172/JCI0214538 Hofbauer, 1999, Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis, Endocrinology, 140, 4382, 10.1210/en.140.10.4382 Lespessailles, 2000, Long-term corticosteroid therapy induces mild changes in trabecular bone texture, J Bone Miner Res, 15, 747, 10.1359/jbmr.2000.15.4.747 Chappard, 1996, Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study, J Bone Miner Res, 11, 676, 10.1002/jbmr.5650110516 Dalle Carbonare, 2001, Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis, J Bone Miner Res, 16, 97, 10.1359/jbmr.2001.16.1.97 Chavassieux, 2000, Effects of alendronate on bone quality and remodelling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies, J Bone Miner Res, 15, 754, 10.1359/jbmr.2000.15.4.754 Walsh, 1996, Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study, Br Med J, 313, 344, 10.1136/bmj.313.7053.344 Van Staa, 2000, Use of oral corticosteroid and risk of fractures, J Bone Miner Res, 15, 993, 10.1359/jbmr.2000.15.6.993 Peel, 1995, Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis, Ann Rheum Dis, 54, 801, 10.1136/ard.54.10.801 Laan, 1993, Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized controlled study, Ann Intern M, 119, 963, 10.7326/0003-4819-119-10-199311150-00001 Peel, 1995, Risk of vertebral fracture and relationship to bone mineral density in steroid treatment of patients with rheumatoid arthritis, Ann Rheum Dis, 54, 801, 10.1136/ard.54.10.801 Selby, 2000, Corticosteroids do not alter the threshold for vertebral fracture, J Bone Miner Res, 15, 952, 10.1359/jbmr.2000.15.5.952 Lane, 1998, Parathyroid hormone treatment can reverse steroid osteoporosis : results of a randomized clinical trial, J Clin Invest, 102, 1627, 10.1172/JCI3914 Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, N Engl J M, 339, 292, 10.1056/NEJM199807303390502 Adachi, 2001, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids, Arthritis Rheum, 44, 202, 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W Cohen, 1999, Risedronate therapy prevents corticosteroid-induced bone loss, Arthritis Rheum, 42, 2309, 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K Reid, 2000, Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial, J Bone Miner Res, 15, 1006, 10.1359/jbmr.2000.15.6.1006 Wallach, 2000, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy, Calcif Tissue Int, 67, 277, 10.1007/s002230001146 Eastell, 2000, Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients, Osteoporosis Int, 11, 331, 10.1007/s001980070122 Adachi, 1997, Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis, N Engl J M, 337, 382, 10.1056/NEJM199708073370603 Roux, 1998, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss, J Clin Endocrinol Metab, 83, 1128, 10.1210/jc.83.4.1128 Adachi, 2000, A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss, J Rheumatol, 27, 2424 Boutsen, 2001, Primary prevention of glucocorticoid-induced osteoporosis with intra-venous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone, J Bone Miner Res, 16, 104, 10.1359/jbmr.2001.16.1.104 Homik, 1999, A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis, J Rheumatol, 26, 1148 Amin, 2002, The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression, J Bone Miner Res, 17, 1512, 10.1359/jbmr.2002.17.8.1512 Israel, 2001, Effects of inhaled glucocorticoids on bone density in premenopausal women, N Engl J M, 345, 941, 10.1056/NEJMoa002304 van Staa, 2001, Use of inhaled corticosteroids and risk of fractures, J Bone Miner Res, 3, 581, 10.1359/jbmr.2001.16.3.581